Journal
CURRENT RADIOPHARMACEUTICALS
Volume 5, Issue 3, Pages 228-243Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1874471011205030228
Keywords
Rhenium-188; W-188/(188) Re generator; Radionuclide therapy; Bone pain palliation; hepatocarcinoma; Rheumatoid arthritis
Ask authors/readers for more resources
Rhenium-188 is one of the most readily available generator derived and useful radionuclides for therapy emitting beta(-) particles (2.12 MeV, 71.1% and 1.965 MeV, 25.6%) and imageable gammas (155 keV, 15.1%). The W-188/(188) Re generator is an ideal source for the long term (4-6 months) continuous availability of no carrier added (nca) Re-188 suitable for the preparation of radiopharmaceuticals for radionuclide therapy. The challenges associated with the double neutron capture route of production of the parent W-188 radionuclide have been a major impediment in the progress of application of Re-188. Tungsten-188 of adequate specific activity can be prepared only in 2-3 of the high flux reactors operating in the World. Several useful technologies have been developed for the preparation of clinical grade 188 W/188 Re generators. Since the specific activity of W-188 used in the generator is relatively low 185 GBq(< 5 Ci)/g], the eluted 188 ReO(4)(-)can have low radioactive concentration often insufficient for radiopharmaceutical preparation. However, several efficient post elution concentration techniques have been developed that yield clinically useful (ReO4-)-Re-188 solutions. Rhenium-188 has been used for the preparation of therapeutic radiopharmaceuticals for the management of diseases such as bone metastasis, rheumatoid arthritis and primary cancers. Several early phase clinical studies using radiopharmaceuticals based on Re-188-labeled phosphonates, antibodies, peptides, lipiodol and particulates have been reported. This article reviews the availability and use of Re-188 including a discussion of why broader use of Re-188 has not progressed as expected as a popular radionuclide for therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available